Advertisement

Topics

Celgene Narrows Its Relationship With Sutro, No Acquisition Coming

07:55 EDT 10 Aug 2017 | Xconomy

Celgene (NASDAQ: CELG) is revamping its relationship with Sutro Biopharma, walking away from an option to acquire the privately held antibody drug developer but keeping potential rights to four of Sutro’s programs—none of which have yet reached clinical studies. Their first deal was in 2012, and they expanded it two years later with Celgene taking […]

Original Article: Celgene Narrows Its Relationship With Sutro, No Acquisition Coming

NEXT ARTICLE

More From BioPortfolio on "Celgene Narrows Its Relationship With Sutro, No Acquisition Coming"

Quick Search
Advertisement
 

Relevant Topics

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...